| Identification | Back Directory | [Name]
Imidazo[1,2-b]pyridazine-3-carboximidamide, N'-cyano-N-ethyl-6-[(2R,4S)-4-fluoro-2-[3-fluoro-5-(methylthio)phenyl]-1-pyrrolidinyl]-, [C(Z)]- | [CAS]
2409544-80-3 | [Synonyms]
TRK-IN-17
Imidazo[1,2-b]pyridazine-3-carboximidamide, N'-cyano-N-ethyl-6-[(2R,4S)-4-fluoro-2-[3-fluoro-5-(methylthio)phenyl]-1-pyrrolidinyl]-, [C(Z)]- | [Molecular Formula]
C21H21F2N7S | [MOL File]
2409544-80-3.mol | [Molecular Weight]
441.5 |
| Hazard Information | Back Directory | [Uses]
TRK-IN-17 is a potent inhibitor of TRK. Tropomyosin-related kinases (Trks) are a family of receptor tyrosine kinases activated by neurotrophins, a group of soluble growth factors including Nerve Growth Factor (NGF), Brain-Derived Neurotrophic Factor (BDNF) and Neurotrophin-3 (NT-3) and Neurotrophin-4/5 (NT-4/5). TRK-IN-17 has the potential for the research of cancer diseases (extracted from patent WO2021148807A1, compound 3)[1]. | [References]
[1] Nicola ROBAS, et al. Pharmaceutical compositions and their uses. Patent WO2021148807A1. |
|
|